TVTX Insider Trading Activity and SEC Form 4 Filings
TVTX insider trading summary
Over the past 12 months, insiders at Travere Therapeutics, Inc. (TVTX) reported 113 sales worth $106.4M by 11 insiders and no open-market purchases on SEC Form 4. Net insider selling was $106.4M.
Latest TVTX insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Oct 15, 2026 | Eric M Dube | Chief Executive Officer | Sell | $2.0M (37,270 @ $54.20) |
| Oct 15, 2026 | Eric M Dube | Chief Executive Officer | Sell | $6.8M (128,065 @ $52.97) |
| Oct 15, 2026 | Eric M Dube | Chief Executive Officer | Sell | $4.3M (78,400 @ $55.02) |
| Sep 17, 2026 | Peter Heerma | EVP, Chief Commercial Officer | Sell | $539K (8,282 @ $65.07) |
| Sep 17, 2026 | Eric M Dube | Chief Executive Officer | Sell | $442K (6,802 @ $64.95) |
| Sep 17, 2026 | Eric M Dube | Chief Executive Officer | Sell | $6.6M (101,691 @ $64.59) |
| Sep 16, 2026 | William E. Rote | Chief Research Officer | Sell | $4.1M (65,104 @ $63.12) |
| Sep 16, 2026 | William E. Rote | Chief Research Officer | Sell | $3.0M (47,746 @ $63.61) |
| Sep 16, 2026 | Peter Heerma | EVP, Chief Commercial Officer | Sell | $5.9M (93,604 @ $63.25) |
| Sep 16, 2026 | Eric M Dube | Chief Executive Officer | Sell | $6.1M (96,125 @ $63.64) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.